Natural product-derived therapy for Myocardial Infarction: Withaferin A (WA), isolated from Ashwagantha, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS, 2/March/2017, 7.21 pm

Anti-telomerase cancer therapy: Ginkgolic acid C 17:1 (GAC 17:1), isolated from Ginkgo biloba leaves, suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and the cellular immortality gene telomerase and inhibits cancer progression via down-regulation of it target gene, 2/March/2017, 6.51 pm
March 2, 2017
Amino acid based therapy for glucose homeostasis and TIIDM: Leucine, an essential amino acid found abundantly in parmesan cheese, soy, and hemp seeds and among others, increases Barr2 expression, augments the functional activity of CAMKII, increases insulin secretion, promotes glucose homeostasis, prevents progression to TIIDM and ameliorates obesity-associated metabolic deficits via down regulation of its target gene, 2/March/2017, 10.29 pm
March 2, 2017
Show all

What they say

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March  2013 issue of Nature  by Prof Dimmler, Boon, and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Natural product-derived therapy for Myocardial Infarction: Withaferin A (WA), isolated from Ashwagantha, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS


From Significance of the study to Public Health relevance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from  123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


From Research Findings to Therapeutic Opportunity

This study provides a natural product-based therapy for myocardial infarction. 

Withaferin A (WA), by increasing the expression of their target genes, it may increase the expression of PNUTS (figs.1-2) . Thereby, it may: (1) inhibit DNA damage responses, (2) increase telomerase expression, (3) inhibit telomere shortening; (4) promote cardiomyocyte survival/regeneration; (5) decelerate ageing; and (6) extend life span (fig 1). 

Withaferin A induces PNUTS expression

Figure 1.Withaferin A (WA) functions as a Cardioprotective agent. Mechanistic insights into how Withaferin A (WA) induces the expression of PNUTS and Telomerase to prevent myocardial infarction and promote Cardiac regeneration/survival

price-300

Thus, by treating patients with Withaferin A (WA), one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that pharmacological formulations encompassing Withaferin A (WA) or its analogs in combination with any of the known compounds that improve myocardial function”  may be used to improve cardiac function after myocardial infarction (fig. 3) 

[easy_payment currency=”USD”]


Details of the research findings

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How  Withaferin A (WA) increases the expression of PNUTS/Telomerase

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web:http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L.,  Natural product-derived therapy for Myocardial Infarction: Withaferin A (WA), isolated from Ashwagantha, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS, 2/March/2017, 7.21 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.